H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Revolution Medicines on Tuesday, setting a price target of $55, which is approximately 67.43% above the present share price of $32.85.
Burns expects Revolution Medicines to post earnings per share (EPS) of -$0.74 for the second quarter of 2020.
The current consensus among 1 TipRanks analysts is for a Moderate Buy rating of shares in Revolution Medicines, with an average price target of $55.
The analysts price targets range from a high of $55 to a low of $55.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $11.55 million and a net profit of -$21.08 million. The company's market cap is $2.09 billion.
According to TipRanks.com, H.C. Wainwright analyst Robert Burns is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 30.5% and a 81.08% success rate.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood (NYSE:RWT) City, CA.